• The study compound may be used to manage body weight in people with severe overweight (obesity). It is intended to be used in combination with increased physical activity and a reduced-calorie diet.
• In this trial we will investigate how quickly and to what extent the study compound is absorbed by the body.
• The study compound has been administered to humans before.
• In group 1 you will receive the study compound a total of three times as a under the skin  injection (in the abdomen, arm or thigh). In group 2 you will receive a solution of the study compound administered directly into a blood vessel via an infusion. This will take around 30 minutes. You can only participate in 1 group of the trial.

The compound has already been tested in healthy participants. In the first trial, a total of 84 healthy adult participants with overweight or obesity received the study compound. Those who received the study compound most often experienced gastrointestinal side effects, such as nausea, vomiting, diarrhea, constipation, and decreased appetite. These side effects were generally not serious and passed quickly.

You may also experience other, yet unknown, side effects. Prior to the medical screening, you will receive written information about the trial, which also describes the possible side effects. This information will also be discussed with you at the start of the medical screening. You can then ask questions to the screening physician or nurse. Once everything is clear to you, you can decide to give written consent to participate in the trial. The medical screening will only take place after you have given written consent to participate in the trial. We want to emphasize that even after giving written consent, participation in any clinical trial is voluntary. You can decide at any time not to participate or to stop the medical screening or the trial. You do not need to provide a reason for why you no longer wish to participate.

• You are a healthy male or female.
• You are at least 18 and at most 65 years old.
• Your weight is at least 55 kg and your Body Mass Index (BMI) is at least 23.0 and at most 35.0 kg/m2. 
• Both non-smokers and smokers or occasional smokers are allowed to participate in this clinical trial (at most 10 cigarettes per day). During your stay in our research facility you are not allowed to smoke.

As a female you can only participate if you are not pregnant, not breast feeding and meet one of the following conditions:

• You use hormonal contraception (for example the contraceptive pill or intra-uterine device containing hormones) in combination with a condom;
• You use a copper intra-uterine device in combination with a condom;
• You have passed the menopause (no periods for at least 12 months);
• You have been sterilized or your male partner has been sterilized;
• You are not sexually active according to your lifestyle;
• You are only sexually active with a partner of the same sex.

As a male you can only participate if you meet one of the following conditions:

• You use a condom with your fertile or pregnant female partner;
• You have been sterilized or your female partner has been sterilized or has passed the menopause (no periods for at least 12 months);
• You are not sexually active according to your lifestyle;
• You are only sexually active with a partner of the same sex.

Note:

• You cannot participate in the trial if you have participated in another clinical trial in the 90 days prior to the first compound administration in this clinical trial (counting from the last administration). This may be longer for certain trials. Please contact us for more information.
• To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.

Group 1

The trial consists of 3 periods during which you will stay each period in the research facility in Groningen (location van Swietenlaan 6) for 6 days (5 nights). Each period is followed by 4 short visits. The follow-up visit will take place during the last short visit.

Group 2

The trial consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 6 days (5 nights), followed by 4 short visits. The follow-up visit will take place during the last short visit.

Note: You must be available for all dates to be able to participate in this clinical trial.